Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Cardiology Department, University of California San Diego Healthcare and Sulpizio Family Cardiovascular Center, La Jolla, CA, USA.
Int J Cardiol. 2022 Oct 1;364:72-76. doi: 10.1016/j.ijcard.2022.06.030. Epub 2022 Jun 20.
Patients hospitalized for heart failure (HF) are at high risk for post-discharge events. Although transition from intravenous to oral diuretics for ≥24 h is commonly practiced to reduce post-discharge risk, evidence supporting this strategy is limited. We investigated the impact of this practice on 30 day post-discharge outcomes following HF hospitalization at our institution.
Retrospective chart review of patients hospitalized with a primary HF diagnosis, discharged on oral diuretic, and followed at our institution. Admission, in-hospital, and pre-discharge characteristics of patients discharged with ≥24-h observation were compared to those of patients observed for <24-h on oral diuretics. Differences between groups in composite 30 day all-cause mortality and rehospitalization, each component, and HF rehospitalization were assessed.
Of 285 patients meeting entry criteria, 178 received oral diuretics ≥24 h prior to discharge and 107 were discharged <24 h after transitioning to oral diuretics. Baseline characteristics were similar between groups. Patients with ≥24 h observation on oral diuretics had longer in-hospital stays and greater weight and net volume loss than those observed <24 h. Patients receiving oral diuretics for <24 h were more likely to have had neurohormonal drugs and diuretic dose changed within 24-h of discharge. Oral diuretic treatment for ≥24 h failed to reduce any study endpoint.
Transitioning patients to oral diuretics for ≥24 h prior to discharge following HF hospitalization failed to improve 30-day outcomes. These results question this strategy for all patients hospitalized for worsening HF.
因心力衰竭(HF)住院的患者在出院后发生不良事件的风险很高。尽管通常会将静脉内到口服利尿剂的转换时间延长至≥24 小时,以降低出院后的风险,但支持这种策略的证据有限。我们调查了我们机构中 HF 住院患者出院后 30 天的结局,以评估这种做法的影响。
回顾性分析我院以 HF 为主要诊断、出院时服用口服利尿剂并在我院接受随访的患者的病历。比较了出院时静脉内到口服利尿剂的转换时间延长至≥24 小时和<24 小时的患者的入院、住院和出院前特征。评估了两组之间复合 30 天全因死亡率和再入院、各组成部分和 HF 再入院的差异。
在符合纳入标准的 285 例患者中,178 例在出院前接受了≥24 小时的口服利尿剂治疗,107 例在出院后<24 小时内从静脉内到口服利尿剂的转换。两组患者的基线特征相似。在口服利尿剂观察≥24 小时的患者中,住院时间更长,体重和净容量损失更大,而在口服利尿剂观察<24 小时的患者中,住院时间更长。在出院后 24 小时内,接受口服利尿剂治疗<24 小时的患者更有可能改变神经激素药物和利尿剂剂量。接受口服利尿剂治疗≥24 小时并不能降低任何研究终点。
HF 住院患者出院前将口服利尿剂转换时间延长至≥24 小时并不能改善 30 天结局。这些结果质疑了对所有因 HF 恶化而住院的患者采用这种策略的合理性。